International Clinical Trial: A Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of KYS202004A Injection in Patients with Plaque Psoriasis with Arthritic Symptoms

Geneva, July 7 -- International Clinical Trials Registry received information related to the study (ChiCTR2600127046) titled 'A Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of KYS202004A Injection in Patients with Plaque Psoriasis with Arthritic Symptoms' on June 23.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Shanghai Sixth People's Hospital

Condition: Plaque Psoriasis with Arthritic Symptoms

Intervention: Dose Group 1 - Investigational Drug Group:KYS202004A Injection, 3.0 mg/kg, intravenous infusion, once every 2 weeks, for a total of 6 doses Dose Group 1 - Placebo Group:KYS202004A Injection Placebo, intravenous infusion, once every 2 weeks,...